Can Augmentin Cause Behavior Changes in a One-Year-Old?
While amoxicillin-clavulanate (Augmentin) is not known to directly cause behavior changes in one-year-olds based on established clinical guidelines and FDA labeling, emerging research suggests a potential association between early-life antibiotic exposure and subsequent neurodevelopmental effects that warrants clinical awareness.
FDA-Approved Safety Profile
The FDA drug label for Augmentin does not list behavioral changes as a recognized adverse effect in pediatric patients 1. The most commonly reported side effects in children are:
- Gastrointestinal: Diarrhea (2.9%), vomiting (2.2%)
- Dermatologic: Diaper rash/contact dermatitis (3.5%), rash (1.1%)
- Other: Moniliasis (1.4%)
Central nervous system effects listed in the FDA label include agitation, anxiety, behavioral changes, confusion, and reversible hyperactivity—but these are reported "rarely" and primarily documented in older populations 1. These are not considered common or expected reactions in one-year-olds.
Guideline-Based Clinical Use
Multiple pediatric infectious disease guidelines consistently recommend amoxicillin-clavulanate as first-line therapy for common bacterial infections in children, including one-year-olds 2, 3, 2, 4, 5:
- For children under 12 years: Co-amoxiclav is the drug of choice for secondary bacterial infections complicating influenza 2
- For acute otitis media and sinusitis: Amoxicillin-clavulanate remains the standard first-line agent 6, 4, 5
- For community-acquired pneumonia: Recommended for children under 5 years, particularly those incompletely vaccinated 3, 7, 8
These guidelines do not highlight behavioral changes as a significant concern limiting the use of this antibiotic.
Emerging Research on Neurodevelopmental Effects
However, recent research raises important questions about potential long-term neurodevelopmental associations with early antibiotic exposure:
Evidence of Association
A 2025 study found that β-lactam antibiotic use (including amoxicillin-clavulanate) before age 3 was associated with high-level hyperactivity in preschool children, with a dose-response pattern related to duration of use 9
A 2017 study of 526 children demonstrated that antibiotic use in the first year of life was associated with more behavioral difficulties and depressive symptoms at ages 3.5,7, and 11 years 10
A 2020 zebrafish model showed that high-dose amoxicillin exposure caused locomotor alterations, decreased social interaction, and oxidative stress in brain tissue 11
A 2005 hypothesis paper proposed a potential mechanism linking clavulanate to neurotoxicity through urea/ammonia production, though this remains unproven in humans 12
Important Caveats
These research findings show associations, not causation. The proposed mechanisms involve:
- Disruption of gut microbiota affecting the gut-brain axis
- Oxidative stress in neural tissue
- Potential metabolic effects of clavulanate
None of these studies demonstrate acute behavioral changes during or immediately after treatment—the effects observed were developmental trajectories assessed months to years later.
Clinical Approach
Immediate Concerns (During Treatment)
If a one-year-old develops behavioral changes while taking Augmentin:
- Consider common adverse effects first: Assess for gastrointestinal discomfort (diarrhea, abdominal pain) that may manifest as irritability or fussiness
- Evaluate for allergic reactions: Rule out rash, urticaria, or other hypersensitivity manifestations that could cause distress
- Assess the underlying infection: Behavioral changes may reflect worsening illness rather than medication effect
- Review for rare CNS effects: Though uncommon, agitation and hyperactivity are listed in the FDA label 1
Long-Term Considerations
Given emerging research, practice judicious antibiotic stewardship 13:
- Use only when bacterial infection is clearly diagnosed using stringent clinical criteria
- Avoid prescribing for viral URIs where benefit is unlikely
- Consider shorter courses when evidence supports equivalence (though this is diagnosis-specific) 14
- Weigh risks vs. benefits particularly in children with recurrent infections requiring multiple courses
When to Discontinue
Discontinue Augmentin if:
- Severe behavioral changes occur (agitation, confusion, severe hyperactivity)
- Signs of serious adverse reactions develop (Stevens-Johnson syndrome, anaphylaxis)
- No clinical improvement after 48-72 hours, suggesting treatment failure 7, 8
Bottom Line
Augmentin does not typically cause acute behavioral changes in one-year-olds during treatment, and it remains guideline-recommended first-line therapy for appropriate bacterial infections. The FDA label lists rare CNS effects but these are not characteristic of typical use in this age group. However, emerging research suggests potential long-term neurodevelopmental associations with early-life antibiotic exposure, reinforcing the importance of prescribing antibiotics only when clearly indicated and using the shortest effective duration. If behavioral changes occur during treatment, evaluate for common adverse effects (GI distress), allergic reactions, or worsening underlying illness before attributing them to direct CNS effects of the medication.